A short dual antiplatelet therapy (DAPT) of 1 to 3 months followed by P2Y12 inhibitor monotherapy after second generation drug eluting stent (DES) implantation is safer and as effective as the traditional scheme. The idea is clear, but why hasn’t aspirin monotherapy been tested as follow up? Is aspirin old fashioned? Are there physiopathological reasons<a href="https://solaci.org/en/2021/04/12/short-therapy-and-monotherapy-plenty-of-evidence/" title="Read more" >...</a>
The Most Read Articles in Interventional Cardiology of March
01- Surgeons’ Claim on Low-Risk Patients with Aortic Stenosis Recent randomized trials including low-risk patients showed positive results for transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement. Read more HERE 02- Major Cause of Myocardial Injury by COVID-19 The most common cause of myocardial necrosis in patient undergoing COVID-19 infection is microthrombi. These<a href="https://solaci.org/en/2021/04/07/the-most-read-articles-in-interventional-cardiology-of-march/" title="Read more" >...</a>
Biodegradable Polymer Myth Also Debunked for ACSs
During TCT 2020 a preview of the results of the comparison of drug-eluting stents (DES) with biodegradable-polymer vs. durable-polymer in patients with acute coronary syndrome (ACS) was presented. The fine print and the final paper for HOST-REDUCE-POLYTECH-ACS are now published, and they lower the expectations set on biodegradable polymers. In patients with ACS undergoing angioplasty, biodegradable-polymer<a href="https://solaci.org/en/2021/04/05/biodegradable-polymer-myth-also-debunked-for-acss/" title="Read more" >...</a>
Revascularization Is Needed Before TAVR
Disease prevalence in patients with severe aortic stenosis is highly variable: from 80% in inoperable patients to only 15% according to the most recent research including low-risk patients. Given the high mortality observed in patients with heart disease, guidelines suggest considering coronary bypass revascularization in those in need of a valve replacement. This experience with<a href="https://solaci.org/en/2021/03/08/revascularization-is-needed-before-tavr/" title="Read more" >...</a>
Diastolic Dysfunction and TAVR: Prognosis before and after Procedure
The PARTNER 2 SAPIEN 3 showed baseline diastolic dysfunction is a predictor of clinical events after 2 years of TAVR. As expected, improved diastolic function after procedure immediately changes prognosis. Though these outcomes did meet our expectations, very few studies have shown hard evidence linking diastolic dysfunction and aortic stenosis. All patients included in the<a href="https://solaci.org/en/2021/03/02/diastolic-dysfunction-and-tavr-prognosis-before-and-after-procedure/" title="Read more" >...</a>
ISCHEMIA: New Analysis Might Change Study Outcome Interpretation
A new ISCHEMIA analysis has shown its outcomes are highly dependent on MI definition. The original conclusion had shown a significant difference between invasive and conservative strategies using the most sensible definition of MI: troponin elevation. When looking at events using MI definition as troponin elevation, we will see the conservative treatment reduces primary end<a href="https://solaci.org/en/2021/02/04/ischemia-new-analysis-might-change-study-outcome-interpretation/" title="Read more" >...</a>
Current DES Performance: Is There Room for Improvement?
Head-to-head comparison of current drug-eluting stents (DES) showed contradictory results that led us to believe, for years, that we had reached a plateau. This feeling was also fostered by the disappointment caused by Absorb and bioresorbable-polymer stents. However, this recent article featured in JACC Interventions shows a light at the end of the tunnel with<a href="https://solaci.org/en/2021/02/02/current-des-performance-is-there-room-for-improvement/" title="Read more" >...</a>
More Evidence for Short Term DAPT: Approaching “the Class Effect”
Patients at high risk of bleeding undergoing coronary angioplasty with Orsiro stent can be considered for a short dual antiplatelet scheme. These data come from the SMART-CHOICE study recently published in JAHA, adding the Orsiro stent to the list of devices supporting 3-month DAPT. This study included 2993 patients undergoing coronary angioplasty randomized to 3<a href="https://solaci.org/en/2021/01/27/more-evidence-for-short-term-dapt-approaching-the-class-effect/" title="Read more" >...</a>
SOLACI PERIPHERAL | 5th Clinical Case: Abdominal Aortic Aneurysm with Hostile Neck
New clinical case from SOLACI PERIPHERAL! This time, we present a case featuring an abdominal aortic aneurysm with hostile neck. With this, we wrap up an intense year during which we published 5 clinical cases to deepen and stimulate the exchange between Latin American interventionist colleagues. Tell us what you think about this case using<a href="https://solaci.org/en/2020/12/23/solaci-peripheral-5th-clinical-case-abdominal-aortic-aneurysm-with-hostile-neck/" title="Read more" >...</a>
The Most Relevant Articles in Coronary Disease in 2020
01- Virtual ACC 2020 | Controversial Trial ISCHEMIA Finally in NEJM In November 2019, during the American Heart Association (AHA) 2019 Scientific Sessions, researchers presented this revolutionary trial that called the attention of all cardiologists. We had to wait until March to read the fine print; back then, a global pandemic such as the current one seemed<a href="https://solaci.org/en/2020/12/17/the-most-relevant-articles-in-coronary-disease-in-2020/" title="Read more" >...</a>